UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Earliest Event Reported): July 11, 2016
CYTRX CORPORATION
(Exact Name of Registrant as Specified in its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
|
000-15327
(Commission File Number)
|
58-1642740
(I.R.S. Employer Identification No.)
|
|
11726 San Vicente Boulevard, Suite 650
Los Angeles, California
(Address of Principal Executive Offices)
|
90049
(Zip Code)
|
(310) 826-5648
(Registrant's Telephone Number, Including Area Code)
______________________________
Check the appropriate box below if the Form 8‑K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a‑12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
| ITEM 7.01 |
Regulation FD Disclosures |
On July 11, 2016, CytRx Corporation ("we," "us," "our" and the "company") issued a press release announcing the initial results of our pivotal Phase 3 trial of aldoxorubicin as a treatment for patients with second line soft-tissue sarcomas. A copy of the press release is attached as Exhibit 99.1 to this Report and incorporated herein by reference.
Also on July 11, 2016, we will host a webcast, as described in the press release, to discuss the initial results. A replay of the webcast will be posted on our website: www.cytrx.com.
The information in this Item 7.01 and Exhibit 99.1 to this Report shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
See the Exhibit Index which immediately follows the signature page thereof and is incorporated herein by reference.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
CYTRX CORPORATION |
|
| |
|
|
|
|
Date: July 11, 2016
|
By:
|
/s/ JOHN Y. CALOZ |
|
| |
|
John Y. Caloz |
|
| |
|
Title: Chief Financial Officer |
|
| |
|
|
|
EXHIBIT INDEX
|
Exhibit No.
|
|
Description
|
| |
|
|
|
99.1
|
|
Press Release of CytRx Corporation issued on July 11, 2016.
|
| |
|
|
| |
|
|
| |
|
|